Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today ...

Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025China and European approval ...